Q2 2026

Filed Aug 13, 2026 · 10-Q · 44 days after period end · 0001477932-26-004958

Q2 2026 · 10-Q

Revenue

$0.00

−100.0% vs Q2 2025

Net Income

-$605.00K

N/M vs Q2 2025

EPS Diluted

-$0.01

N/M vs Q2 2025

Gross Profit$0−100.0%

Operating Income

Same quarter

Metric	Q2 2026	Q2 2025	Q2 2024	Q2 2023
Revenue	$0.00	$117.00K	$0.00	$44.00K
Net Income	-$605.00K	-$811.00K	-$709.00K	-$1.56M
EPS Diluted	-$0.01	-$0.01	-$0.01	-$0.03

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Guided Therapeutics Inc · CIK 924515 · Engraved from SEC EDGAR